A medical oncologist and internist at a Southwest Comprehensive Cancer Center discusses their use of MRD / ctDNA monitoring. They utilize these technologies most often in melanoma patients but expect there to be more uptake of these tests in other common cancers such as lung, CRC, breast, and prostate. A major hindrance to their recommendation of using these tests is around lack of clinical data and guideline inclusions, in which they imagine vendors who release reputable data the most quickly will see the most success in this market. They are most familiar with Guardant and Natera as vendors in this space and are decently satisfied with both providers. They mentioned time to market / both these companies being early movers were key to their success.

Campaign Details

MRD Ad Board

DeciBio conducted ~11 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care